Please login to the form below

Not currently logged in
Email:
Password:

aripiprazole

This page shows the latest aripiprazole news and features for those working in and with pharma, biotech and healthcare.

Teva’s weak pipeline hit by Tourette’s drug trial failure

Teva’s weak pipeline hit by Tourette’s drug trial failure

110 and Otsuka’s well-established antipsychotic drug Abilify (aripiprazole), which is in a trial with data due next year.

Latest news

More from news
Approximately 6 fully matching, plus 59 partially matching documents found.

Latest Intelligence

  • Tools for the digital world Tools for the digital world

    In May Proteus and Otsuka Pharmaceutical Co resubmitted a New Drug Application for the drug-device combination product of Ablify (aripiprazole) embedded with a Proteus ingestible sensor in a single tablet.

  • Pharma deals during March 2013 Pharma deals during March 2013

    At the end of February, the FDA approved Abilify Maintena (aripiprazole), an intramuscular extended-release depot formulation for the treatment of schizophrenia and the first commercialised product to evolve from this

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Jet Off with Maloff Protect

Latest intelligence

Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....